Background: Balloon aortic valvuloplasty (BAV) has often a compassionate rule in the treatment of symptomatic and severe aortic stenosis (AS). Aim of this work was to evaluate the clinical outcomes of BAV performed in emergency clinical setting. Methods: Between September 2007 and September 2012, forty-two consecutive emergency BAV were performed because of severe AS symptomatic for refractory pulmonary edema (71%) or cardiogenic shock (29%). Results: Most of the patients were female (60%) with mean age of 86AE5 years and Logistic Euroscore I of 40AE21%. Baseline echocardiographic data showed an aortic valve area of 0.5AE1.4 cm2 and a mean transvalvular gradient of 46AE14 mmHg, high pulmonary hypertension (50AE15 mmHg) and left ventricular ejection fraction of 41AE14%. Coronary artery disease was present in 52%, with multivessel disease in 24% of the cases. During BAV, a coronary revascularization was performed in 26% of the pts. An undersized balloon (20 mm) was used in 71% of cases. Drop of 33AE20 mmHg of peak aortic gradient was observed after BAV and in 57% of the procedures one balloon inflation was enough. In-hospital death rate was 28%. All-cause death at 6 months was 45%. Transcatheter aortic valve replacement (TAVR) was performed in 56% of survival pts with a significant improvement in clinical outcomes (NYHA class II and no mortality at 6 months follow up in all pts). Conclusions: Although high mortality rate was observed after BAV in emergency clinical setting (refractory pulmonary edema or cardiogenic shock due to severe AS) survival pts had a chance to be able to complete the treatment of AS by TAVR procedure.
Baylor Healthcare System, Plano, United States, 11 Henry Ford Hospital, Detroit, Michigan Background: BNP is synthesized in cardiac ventricular tissue in response to increased wall stress and is known to be elevated in patients with aortic stenosis, especially those with clinical heart failure. We sought to characterize the timing and prognostic significance of changes in BNP levels after TAVR in the PARTNER I trial. Methods: A total of 801 patients treated with transfemoral (TF) TAVR had BNP levels determined at baseline, 1w, 6 m, 12 m, and 24 m after therapy. We further divided patients into Group I (those with rising BNP levels at 1m) and Group II (those with stable or falling BNP). Results: Median Baseline BNP [IQR] was 619 [293, 1438] , falling to 610 [289, 1342] at 1w and 479 [238, 1006] at 1m. Thereafter, BNP levels remained stable at 6m (357 [175, 827] ), 1y (341 [176, 729] ), and 2y (346 [187, 782] ). Mortality was increased at 6m, 1y, and 2y for patients with rising BNP (See figure) . Similarly, repeat hospitalization was higher at 6m (18 vs 10%, p¼0.0008), 1y (24 vs 13%, p¼0.0002), and 2y (40 vs 31%, p¼0.006). Patients in Group I were more likely to have moderate/severe AR post-procedure (14.7 vs 9.3%, p¼0.03596). Moderate or severe mitral regurgitation was similar between Group I and Group II at 1m echo (24 vs 18%, respectively, p¼0.08), but was more common in Group I patients on the 6m echo (25 vs 16%, p¼0.02). Conclusions: BNP levels are elevated and tend to fall rapidly after TF-TAVR. Rising BNP levels after TAVR are associated with a significantly increased risk of death or rehospitalization and post-procedure moderate/severe AR.
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Circulatory Support is Associated with Higher Mortality During TAVR Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania Background: Circulatory support (CS) may be needed during TAVR, but little is known about the incidence, outcomes, and predictors of its use. Methods: The study population included all patients in the PARTNER trial and Continued Access Registry (CAR) that underwent TAVR. Patients that received CS (intra-aortic balloon pump [IABP] or cardiopulmonary bypass [CPB] ), either elective pre-procedure or urgent intra-procedure, were compared to patients that did not receive CS. Results: Of the 2538 patients, 203 (8%) received support, including CPB (n¼133, 66%) or IABP (n¼70, 34%). Compared to those not receiving support, patients receiving CS were more likely male (64% vs 51%, p< 0.0001), undergo transapical access (81% vs 39%, p<0.0001), have prior CABG (60% vs 41%, p < 0.0001), lower left ventricular EF (47 vs 53%, p<0.001), and moderate or severe mitral regurgitation (28% vs 21%, p ¼ 0.03). The incidence of CS was higher in the CAR than in the PARTNER trial (9% vs 5%), partly due to an increased proportion of transapical cases (50% vs 20%, respectively). The use of circulatory support was associated with greater procedural complications, including major vascular complications (17% vs 5%, p< 0.0001) and valve embolization (5% vs 0.5%, p<0.0001). CS was associated with a significantly higher 30 day all-cause mortality (25% vs 5%, p< 0.0001), and was higher in patients that received CPB compared to IABP (32% vs 13%, p¼0.003). The mortality difference between the CS and non-CS groups persisted at two years (48% vs 28%, p< 0.0001). The specific indication for CS, elective pre-procedure or urgent resulting from a complication, will be separately analyzed to determine the effect on outcome. Conclusions: The use of CS during TAVR is surprisingly frequent, associated with procedural complications, and portends a higher early and late mortality. CS was used more frequently in registry patients as compared to randomized trial patients. Identifying patients most likely to benefit from CS may represent an opportunity to improve outcomes. www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM transfemoral (TF) route in the catheterization laboratory (C-TF) or hybrid room (OR-TF) and OR non-TF TAVR. Methods: A retrospective study was performed on 174 patients who underwent TAVR at a single US academic institution using the SAPIEN valve from 11/2011 to 4/ 2013. Patients were stratified into 3 groups: C-TF TAVR (n¼51), OR-TF TAVR (n¼39), and OR-non-TF TAVR (n¼84). All C-TF patients were performed with i.v. sedation and TTE. The OR-TF and OR-non-TF patients were performed in the hybrid OR with general anesthesia and TEE. Total variable cost, hospital payment, and contribution margin were utilized to determine the financial viability of TAVR. Results: Compared to OR-TF and OR-non-TF, C-TF had a significantly lower procedure time (p<0.001) and postop ventilator hours (p<0.001). Resource utilization in terms of ICU (p<0.001), postop (p<0.001), and total hospital LOS (p<0.001) was significantly higher in OR-non-TF patients. Total variable cost in the OR-non-TF TAVR was the highest ($57, 197AE23, 142) , but hospital payment was comparably the highest ($62,647AE58,826); leading to the highest contribution margin ($19, 594AE43, 553) . Total variable cost and hospital payment were lowest in the C-TF group, leading to a contribution margin of $15,529AE19,556 (Table) .
Conclusions: This is the first study comparing the economic impact of the minimalist and standard approaches to TAVR. The economic benefits of TAVR in all groups were shown to be financially viable (positive contribution margin). Resource utilization was the least in the C-TF group, but hospital reimbursement was also the lowest. A more defined reimbursement strategy for these high-risk patients is required. (range, 85-99) . TF access was used in 81% and alternative approaches in 19% of cases (16% TA and 2.5% DA). Sex female was higher in TF (64% vs 50%, respectively, p¼0.014) while the Logistic Euroscore I was higher in the second group (21% vs 26%, respectively, p¼0.039), as well as the presence of coronary artery disease (41% vs 58%, p¼0.004) and history of myocardial infarction (14% vs 23%, respectively, p¼0.036). There was non significant difference regarding to devices success between two approaches (95% vs 96%, respectively, p¼0.8). Combined early safety end point was similar between two groups (28% vs 22%, respectively, p¼0.23), as well as the individual components, except for a significant higher incidence of acute kidney injury (stage II-III) in TF compared to alternative accesses (30% vs 17%, respectively, p¼0.010). All-cause of death and cardiovascular death at 30 days and 1 year of follow up were similar into two groups irrespective of different type of vascular access. Conclusions: When TF approach was not feasible because of anatomical reasons, the alternative approach such as axillary artery (TA) or, more recently, direct ascending aorta (DA) could lead to a self-expandable valve implantation safely also in elderly patients.
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Long Table. Conclusions: In this real world Brazilian registry, nonagenarian pts who underwent TAVI had favorable and similar early-and long-term clinical outcomes as compared with pts < 90 years. The treatment of symptomatic severe aortic stenosis in nonagenarians pts with TAVI deemed to be a non-futility approach. 
